ABSTRACT
Acute megakaryoblastic leukemia (AMKL) accounts for up to 15% of childhood acute myeloid leukemias (AMLs). 1 When not associated with Down syndrome (DS), AMKL has historically represented a high-risk AML subtype associated with a poor prognosis. 2 However, recent insights into the genomic landscape of pediatric non-DS AMKL have led to the characterization of multiple genetically defined subsets of AMKL with heterogeneous outcomes, the identification of which can facilitate more precise risk classification and improved treatment planning, including the decision to pursue allogeneic stem cell transplantation in complete first remission for patients with specific high-risk fusion events. 3 Of note, translocations that characterize two particularly high-risk AMKL subsets (CBFA2T3-GLIS2 and NUP98-KDM5A, together found in 30% of pediatric non-DS AMKL) may not be detected by conventional cytogenetics and require either fluorescence in situ hybridization or molecular testing for diagnosis. 3 Since some standard AML ancillary testing panels may not currently account for these fusions, the immunophenotypic diagnosis of AMKL can be critical in ensuring these aberrations are screened for. A sensitive and reliable approach to the identification of megakaryocytic differentiation in leukemic blasts can thus be the first step in achieving optimal outcomes for pediatric patients with AMKL.
The diagnosis of AMKL is established by the presence of 20% or more blasts in the bone marrow or peripheral blood, of which at least 50% must demonstrate immunophenotypic evidence of megakaryocytic differentiation either by flow cytometry (FC) and/or immunohistochemistry (IHC).
Since most AMKL cases are associated with extensive myelofibrosis, 5 bone marrow aspirate smears can be of limited utility in morphologic blast enumeration, potentially leading to underestimation of the total blast count. 6 Aspirate cellularity may also be inadequate for immunophenotyping by FC. In such cases, enumeration of blast percentage, as well as lineage identification, is most reliably performed on IHCstained paraffin-embedded trephine sections. In addition, platelet satellitism can produce false positivity for megakaryocytic markers on FC, which in some circumstances can render immunohistochemical staining of the biopsy the only reliable means of lineage determination. 7 Per World Health Organization (WHO) criteria, establishment of megakaryocytic lineage requires expression of at least one platelet glycoprotein: CD41 (glycoprotein IIb/ IIIa), CD61 (glycoprotein IIIa), or CD42 (glycoprotein Ib). 4 However, to date, no study has sought to characterize the relative performance of these markers in identifying blasts of megakaryocytic lineage. Here, we evaluate the sensitivity of three commercially available immunohistochemical stains used for the identification of megakaryoblasts within the context of pediatric AMKL and correlate these findings with available flow cytometric studies.
Materials and Methods

Case Selection
Following approval from the St Jude Children's Research Hospital Institutional Review Board, an institutional database was searched for all cases of AMKL diagnosed over a 10-year period. Bone marrow biopsy specimens, corresponding FC studies (when available), and the electronic medical record were reviewed. Consistent with 2017 WHO classification guidelines, selected cases demonstrated 20% or more blasts in the peripheral blood or bone marrow, with 50% or more exhibiting megakaryocytic differentiation as evidenced by expression of CD41, CD61, and/or CD42b by immunohistochemical staining and/or FC. 4 Positivity by IHC was defined as diffuse membranous/cytoplasmic staining in 50% or more of blasts.
Bone Marrow Biopsy Specimen Preparation
Bone marrow biopsy specimens were initially fixed in B-Plus Fixative (BBC Biochemical, Mount Vernon, WA) for 2 to 24 hours. Following fixation, biopsy specimens were placed in EDTA disodium salt formalin solution and kept in a shaking water bath maintained at 45°C for overnight decalcification. The specimens were subsequently processed on a Leica PELORIS Dual Retort Rapid Tissue Processor (Leica Biosystems, Buffalo Grove, IL) using the bone marrow protocol. Once embedded in paraffin, sections were cut at a thickness of 3 μm, mounted on glass slides, and stained.
IHC
CD42b
Staining for CD42b was performed on a Ventana BenchMark ULTRA automated platform (Ventana Medical Systems, Tucson, AZ). Following deparaffinization with EZ Prep (Ventana Medical Systems), pretreatment heat-induced epitope retrieval (HIER) using Cell Conditioning 1 buffer (Ventana Medical Systems) was performed for 32 minutes. Rabbit anti-human CD42b monoclonal antibody (clone SP219; Spring Bioscience, Cambridge, MA) was diluted 1:100 and incubated at 37°C for 16 minutes. Detection was performed with the OptiView DAB kit (Ventana Medical Systems) per the manufacturer's instructions.
CD61
Staining for CD61 was performed on a Dako Omnis automated platform (Agilent Technologies, Santa Clara, CA). Following deparaffinization with Clearify solution (Dako, Carpinteria, CA), pretreatment HIER was performed using the EnVision FLEX Target Retrieval Solution, High pH (Dako) for 30 minutes at 96°C. Mouse anti-human CD61 monoclonal antibody (clone Y2/51; Dako) was diluted 1:50 and incubated at 36°C for 20 minutes, followed by a 10-minute incubation with EnVision FLEX Mouse LINKER (Dako) for signal amplification. For detection, the EnVision FLEX kit (Dako) was used per the manufacturer's instructions.
von Willebrand Factor
Staining for von Willebrand factor (vWF) was performed on a Leica Bond III automated platform (Leica). Deparaffinization was performed using BOND Dewax solution (Leica Biosystems). Pretreatment HIER was performed for 20 minutes with Epitope Retrieval Solution 2 (Leica Biosystems). Mouse anti-human vWF monoclonal antibody (clone F8/86; Dako) was diluted 1:25 and incubated for 15 minutes at room temperature. For detection, the Bond Polymer Refine Detection system (Leica Biosystems) was used per the manufacturer's instructions.
FC
Peripheral blood and bone marrow samples were collected in preservative-free heparin or EDTA anticoagulant. Cells were washed twice in phosphate-buffered saline and labeled with various combinations of monoclonal antibodies conjugated to fluorochromes directed against surface antigens or isotype-matched nonreactive monoclonal antibodies. The specific antibodies evaluated in this study were anti-CD41-FITC (clone P2; Beckman Coulter, Atlanta, GA), anti-CD42b-PE (clone SZ2; Beckman Coulter), and anti-CD61-FITC (clone RUU-PL7F12; BD Biosciences, San Jose, CA). After incubation for 10 minutes at 20°C in the dark, 2 mL FACS Lysing Solution (Becton Dickinson, San Jose, CA) was added to each of the tubes, which were then incubated for 10 minutes in the dark at room temperature. Cells were subsequently washed using an UltraCW Cell Washer (Helmer Scientific, Noblesville, IN) and analyzed using four-or eight-color stained cell preparations with FACSCalibur or FACSCanto II flow cytometers with CellQuest Pro or FACSDiva software (Becton Dickinson).
Results
A total of 32 patients with confirmed AMKL were identified, among whom seven (21.9%) had DS. IHC reactivities of antibodies to CD42b, CD61, and vWF were compared to the corresponding FC studies (summarized in ❚Table 1❚ and ❚Table 2❚). Three cases did not have corresponding FC because of inadequate bone marrow aspirate cellularity. The typical positive staining patterns for each IHC marker are shown in ❚Image 1❚. The sensitivity of the immunohistochemical stains for CD42b, CD61, and vWF was 90%, 78.1%, and 62.5%, respectively. ❚Image 2❚ demonstrates one of two cases that by IHC was positive for CD42b but negative for CD61 and vWF. Of three cases that were negative for CD42b, two were also negative for CD61 and vWF while one was positive for both CD61 and vWF.
By FC, all cases were positive for at least one platelet glycoprotein while negative for cyCD3 and CD19. One case showed dim subset positivity for cyMPO, but no evidence of MPO expression could be confirmed by cytochemical staining. CD41 and CD61 both demonstrated 100% sensitivity, whereas the sensitivity of CD42b was only 80%. There were two cases in which CD61 and CD41 1 P P N BM P P P 2 P P P BM P P P 3 P P P BM P P P 4 P P P BM P P P 5 P P P BM P P P 6 P P P BM P P X 7 P P N BM P P P 8 N P N PB P P P 9 P P P PB P P P 10 P P P BM P P P 11 ❚Image 1❚ Bone marrow biopsy specimen with megakaryoblasts positive for all three megakaryocytic antigens. A, H&E stain shows a hypercellular marrow extensively infiltrated by megakaryoblasts (×200). The megakaryoblasts are strongly positive for CD42b (B) and CD61 (C) (×200; insets, ×1,000). D, von Willebrand factor stains positively in a smaller subset of megakaryoblasts than the other two stains and also produces background staining due to its reactivity with endothelial cells (×200; inset, ×1,000). 
Discussion
This study represents the largest contemporary series investigating the differential sensitivities of megakaryocytic immunohistochemical and flow cytometric markers used in the diagnosis of AMKL. FC, as expected, was the most sensitive modality for immunophenotyping the leukemic clone, with CD61 and CD41 delivering a sensitivity of 100% (Table 2 ). It should be noted that the historical dilemma of AMKL-associated myelofibrosis preventing the collection of an adequately cellular specimen for flow cytometric immunophenotyping can be circumvented in many cases by performing FC on the peripheral blood, which recent studies have confirmed to be highly sensitive and specific for the diagnosis of acute leukemia. 8, 9 Consistent with recently published data, peripheral blood FC in this study, when performed, demonstrated 100% sensitivity for the identification of blasts of megakaryocytic lineage.
Although FC is more sensitive than IHC, its utility is limited when circulating megakaryoblasts are absent, the ❚Image 2❚ Bone marrow biopsy specimen in which the megakaryoblasts are positive for CD42b while negative for CD61 and von Willebrand factor (vWF). A, H&E demonstrating a hypercellular marrow with increased blasts (×400). Whereas by flow cytometry, the megakaryoblasts were positive for CD42b and CD61, by immunohistochemistry, only CD42b was positive and thereby capable of providing immunophenotypic confirmation of megakaryocytic differentiation as well as facilitating relative blast quantitation (B, ×400; inset, ×1,000). C, CD61 highlights an infrequent megakaryocyte, which serves as a positive internal control, but does not stain positively in the megakaryoblast population (×200; inset, ×400). D, vWF stains endothelial cells, which serve as a positive internal control, but similar to CD61 does not stain the blasts (×200; inset, ×400). marrow is inaspirable, or antibodies against megakaryocytic markers are not present in the flow panel. When FC data are not available, the most sensitive IHC stain for identifying megakaryoblasts in EDTA-decalcified paraffin-embedded bone marrow trephine sections is CD42b, which provides a sensitivity of 90.6%. Our results are similar to a previous small study of AMKL that showed CD42b IHC positivity in all 10 cases, 10 but our study demonstrates that IHC for CD42b can be negative in approximately 10% of cases.
❚Image 3❚ Although uncommon, megakaryocytic markers may be detected by flow cytometry (FC) but not immunohistochemistry (IHC) (6.3% of patients in this study). By FC, the blasts in this case were positive for CD61 (A) and CD41 (B) but negative for CD42b. C, IHC for CD42b (×100), the most sensitive stain for the identification of megakaryoblasts, is negative, as were stains for CD61 and von Willebrand factor (not shown). Inset highlights two megakaryocytes, which serve as a positive internal control (×400).
CD45 APC-H7-A
❚Image 4❚ CD42b in this case is detected by immunohistochemistry (IHC) but not flow cytometry (FC). A, By FC, the blast population is positive for CD41 but negative for CD42b (B). C, Bone marrow biopsy specimen stained for CD42b demonstrates strong and extensive cytoplasmic positivity among the megakaryoblasts (×200; inset, ×1,000). The discrepancy between FC, and IHC is likely related to the early maturational stage of the megakaryoblast clone in which CD42b is expressed intracellularly but has yet to completely undergo surface presentation, rendering it undetectable by FC. Grans, granulocytes; Interest, blasts and gate for B; Lymphs, lymphocytes; Monos, monocytes.
Two of the three cases that were negative for CD42b by IHC were also negative by IHC for CD61 and vWF. By FC, however, both were positive for CD41 and CD61 while negative for CD42b. While the discrepancy between FC and IHC may raise suspicion for platelet satellitism, the absence of CD42b expression, which would be expected to be expressed by platelets, argues against this possibility. Furthermore, the blasts in both cases demonstrated expression of myeloid-associated antigens characteristic of AMKL (CD13 and CD33) and were negative for cyCD3 and CD19. By cytochemistry, the blasts were negative for both MPO and ANB. The most likely explanation for the IHC negativity in these cases is that the megakaryoblasts were very poorly differentiated with limited megakaryocytic antigen expression, which was only detectable by FC owing to its superior sensitivity.
While CD42b was the most sensitive IHC stain for the identification of megakaryoblasts, it represented the least sensitive antibody by FC (80% sensitivity) ( Table 2) . Three cases were negative by FC but positive by IHC (Image 4). One possible explanation for the discordance between the rates of flow cytometric and IHC detection of CD42b may be that the megakaryoblasts in these three cases expressed cytoplasmic but not surface CD42b. A similar phenomenon has been documented with CD61, which is expressed in the cytoplasm prior to undergoing surface presentation.
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Although this is the first study to directly compare the sensitivity of the three most commonly employed, commercially available megakaryocytic markers, the finding that CD42b outperforms vWF is consistent with previously published data by Orazi et al. 10 As in our study, vWF performed relatively poorly in terms of its ability to identify blasts of megakaryocytic lineage as well as in its overall ease of interpretation, which can be obscured by varying amounts of nonspecific background staining (Image 1D). The low sensitivity of vWF (62.5% in our study) likely reflects decreased expression of vWF in AMKL with poorly differentiated blasts. 10 Of note, there was not a single case in our study in which vWF identified megakaryoblasts when neither CD42b nor CD61 could. Thus, based on the results of this study, we do not recommend the routine use of vWF when CD42b and CD61 are available.
A limitation of this study is that IHC for CD41, which has become available in recent years, was not evaluated since this stain is not included in our institutional panel. Although CD41, along with CD61, demonstrated 100% sensitivity by FC, there is a paucity of data in the literature characterizing the sensitivity of CD41 IHC in the context of AMKL. The utility of CD41 IHC for the diagnosis of AMKL, particularly in relation to CD42b and CD61, thus remains an area for future investigation.
In summary, this study provides the largest and first dedicated comparative evaluation of the three most commonly used commercially available immunohistochemical stains for the identification of megakaryoblasts in AMKL. CD42b has a 90.6% sensitivity for the detection of megakaryoblasts. When combined with CD61, the overall sensitivity increases to 93.6%. For the detection of megakaryoblasts, we therefore recommend IHC for CD42b and CD61 but not vWF.
